Diabetes Care Was a Monologue. We Made It a Conversation.

A continuous glucose monitor collects a reading every five minutes. That's 288 readings a day. 8,640 a month. 103,680 a year. And then it waits -- usually for ninety days, until a fifteen-minute appointment -- for someone to actually do something with them.

For two decades, this has been the unspoken math of modern diabetes care. We built a sensor revolution. We skipped the conversation revolution. And outcomes stalled on the gap between the two.

The Loneliest Number in Medicine: 103,680

No other chronic condition generates data at this scale. A hypertension patient takes a blood pressure reading once a day at most. A heart-failure patient logs daily weights. Diabetes produces more than a hundred thousand data points per patient per year -- enough to fill a book the length of Anna Karenina every seven weeks.

And then those readings land in a PDF report, a traffic-light pie chart, or a time-in-range number scrolled at a 90-day follow-up. The sensor speaks. Almost nobody listens.

Sources: International Diabetes Federation; ADA Economic Costs of Diabetes in the U.S., 2022; CDC National Diabetes Statistics Report. CGM reading count assumes the standard 5-minute sampling interval (288 readings/day × 360 days).

What a Monologue Feels Like

Here is the status quo on a single Thursday, seen from both sides of the same glucose reading.

Both sides are staring at the same data, at the same time, and neither can use it. The patient has a question nobody answers. The clinician has an answer nobody has time to find. That is what a monologue feels like.

What a Conversation Does Instead

Imagine the same Thursday, but the data can talk back. Not with more alerts. With answers.

The assistant sits above whichever sensor the patient already wears -- Dexcom, Libre, Medtronic, a future device that hasn't shipped yet. It reads the glucose stream continuously, pulls in meals, medication timing, sleep, activity, labs, and prior visit notes, and gives both the patient and the clinician a partner they can actually talk to. In their own words. In plain language. With reasoning they can check.

Here is what the Thursday above looks like when the data has a voice.

Monologue vs. Conversation, Line by Line

Two eras. Two experiences of the same sensor data.

When Data Talks Back, Outcomes Follow -- and Cost Follows Outcomes

This isn't a story about software. It's a story about what happens when the feedback loop finally closes.

The clinical literature is remarkably consistent on one point: in diabetes, time in range -- the percentage of the day spent between 70 and 180 mg/dL -- is the modifiable number that changes everything downstream. Every ten-percentage-point increase in time in range corresponds to roughly a 0.8-percentage-point drop in HbA1c (Vigersky & McMahon, Diabetes Technology & Therapeutics, 2019). Lower A1C drives lower complication rates. Lower complication rates drive lower cost.

None of these mechanisms are new. The UKPDS trial documented them in 1998. What's new is that the feedback loop required to actually move these numbers -- the daily, meal-by-meal, patient-by-patient conversation -- has always been impossibly expensive to staff at scale. One endocrinologist can hold 15 minutes of meaningful conversation with maybe forty patients a week. Multiply that by 537 million people and you see the wall we've been running into for twenty years.

A conversational layer that scales doesn't replace the clinician. It makes the clinician's expertise available to the patient on the day it's needed, instead of in the quarter it's scheduled.

And the Practice Gets Paid for Doing It

Here is the part that surprises people. The economics of diabetes care between visits were already written by Medicare, years before any of this technology existed. Four care-management programs -- Chronic Care Management (CCM), Remote Patient Monitoring (RPM), Principal Care Management (PCM), and Remote Therapeutic Monitoring (RTM) -- exist specifically to reimburse the work of managing a chronic disease in the twenty-nine days between office visits.

Most practices don't bill them. Not because they don't qualify. Because the documentation burden eats the margin.

So the conversation layer does three things at once -- and they reinforce each other. It gives the patient a partner. It gives the clinician leverage. And it turns the care coordination work that used to be uncompensated into a billable line on the practice's ledger.

The 537 Million Opportunity

One in ten adults on Earth has diabetes. By 2045, the International Diabetes Federation projects that number will rise to roughly 783 million. Almost every healthcare system in the developed world is already spending 10-20% of its health budget on diabetes and its complications. Almost every system in the developing world is watching those costs accelerate while its clinical workforce runs flat.

You can't solve that problem with more sensors. You can't solve it with more endocrinologists -- the pipeline is not growing fast enough, and even if it were, it would take a generation. The only way the math works is if the conversation scales. If the moment of interpretation -- the thing a great diabetes educator does on a great day -- becomes available to any patient, any clinician, in any language, at any hour.

That is not a technology story. That is an outcomes-and-cost story, which is the only story that matters at 537 million.

The New Picture

Fifteen years ago, diabetes care crossed a threshold: the sensor started producing more information than any human could use. We celebrated that as a victory. It was only half of one.

The second half is now here. The data finally has a voice. Patients get a partner who explains, teaches, and coaches -- in their own language, in their own kitchen, at the moment the question actually matters. Clinicians get a fellow who reads every reading, drafts every note, and surfaces only the patients and the patterns that need a human decision. Practices get paid for the work that was already required to run a modern chronic care program. Health systems get a path to better outcomes that doesn't require a clinical workforce they can't hire.

And the sensor -- the brilliant, patient, tireless sensor -- finally gets to be part of a conversation instead of giving a speech nobody has time to attend.

Diabetes care was a monologue. It doesn't have to be anymore.

Sources

• International Diabetes Federation. IDF Diabetes Atlas, 10th edition (2021) and projections to 2045.
• Parker ED, Lin J, Mahoney T, et al. "Economic Costs of Diabetes in the U.S. in 2022." Diabetes Care, American Diabetes Association, 2024.
• Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2024.
• Vigersky RA, McMahon C. "The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes." Diabetes Technology & Therapeutics, 2019.
• Battelino T, Danne T, Bergenstal RM, et al. "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range." Diabetes Care, 2019.
• UK Prospective Diabetes Study (UKPDS) Group. "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35)." BMJ, 2000.
• Centers for Medicare & Medicaid Services. Care Management Services fact sheets: CCM, RPM, PCM, RTM.
• CGM reading count: derived from standard 5-minute sampling interval (288 readings × 360 days ≈ 103,680/year). Sampling interval per Dexcom, Abbott FreeStyle Libre, and Medtronic device specifications.